预约演示
更新于：2026-05-12
Moxifloxacin Hydrochloride
盐酸莫西沙星
更新于：2026-05-12
概要
基本信息
原研机构 |
非在研机构 |
权益机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C21H25ClFN3O4 |
InChIKeyIDIIJJHBXUESQI-DFIJPDEKSA-N |
CAS号186826-86-8 |
关联
467
项与 盐酸莫西沙星 相关的临床试验NCT07485010
A Multi-centre, Randomised Trial Comparing a Novel Combination Treatment (Arm D - Intravenous Sulbactam-durlobactam in Combination With Intravenous Ceftriaxone, Oral Amoxicillin, Oral Azithromycin and Oral Clofazimine) Versus Standard of Care Treatments for the Intensive Phase of Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
NCT03244072
Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery
CTIS2025-524484-20-00
Rapid Oral Switch in Infectious Endocarditis, the ROSIE trial
100 项与 盐酸莫西沙星 相关的临床结果
登录后查看更多信息
100 项与 盐酸莫西沙星 相关的转化医学
登录后查看更多信息
100 项与 盐酸莫西沙星 相关的专利（医药）
登录后查看更多信息
9,526
项与 盐酸莫西沙星 相关的文献（医药）2026-07-01DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Mycobacterium avium complex presenting as an infected epidermal inclusion cyst of breast: a rare case report
Article
作者: Ahuja, Sana ; Sureka, Niti ; TeenaTeena ; Chohan, Shikhar ; Zaheer, Sufian
INTRODUCTION:
Non-tuberculous mycobacteria (NTM), including Mycobacterium intracellulare, are opportunistic pathogens mostly affecting immunocompromised individuals. Cutaneous involvement is rare and can mimic other diseases. Epidermal inclusion cysts (EICs) are benign and uncommon in the breast. MAC infection within an EIC is extremely rare and complicates diagnosis.
CASE PRESENTATION:
A 21-year-old immunocompetent woman presented with a painful, progressively enlarging right breast mass over six months. Examination revealed an erythematous swelling with draining sinus. Imaging suggested an abscess or infected cyst. FNAC showed squamous cells and inflammation. Ziehl-Neelsen stain and Mycobacteria Growth Indicator Tube (MGIT) culture confirmed MAC. She received amikacin, moxifloxacin, clarithromycin, and linezolid for 12 months with full resolution.
CONCLUSION:
This case illustrates an unusual MAC infection in a breast EIC in an immunocompetent patient and emphasizes the need for microbiological studies in persistent breast lesions for accurate diagnosis and treatment.
2026-07-01JOURNAL OF MOLECULAR GRAPHICS & MODELLING
Molecular dynamics simulations to investigate Mycobacterium tuberculosis DNA-gyrase-fluoroquinolone complexes
Article
作者: Lessigiarska, Iglika ; Diukendjieva-Todorova, Antonia ; Pencheva, Tania ; Nikolova-Kejova, Radostina ; Alov, Petko ; Pajeva, Ilza ; Tsakovska, Ivanka
The widespread use of fluoroquinolone antibiotics to treat Mycobacterium tuberculosis (Mtb) infections has led to a rise in fluoroquinolone-resistant Mtb strains, mainly due to specific mutations in the target DNAgyrase. To overcome this resistance and develop treatment alternatives, a deeper understanding of fluoroquinolone's mechanism of action is necessary. In this study we performed molecular dynamics (MD) simulations on experimentally derived complexes of wild-type and Ala90Ser mutated Mtb DNA gyrase with three fluoroquinolones - moxifloxacin, gatifloxacin, and levofloxacin. The differences in binding among the three drugs and the impact of the Ala90Ser mutation were analyzed at molecular level. Key interactions between gyrase amino acids, DNA nucleotides, and Mg2+ cofactor with the fluoroquinolone ligands, were identified. The ranking of fluoroquinolones according to the stability of their DNA-gyrase complexes, binding energies, and key binding site residues, was in accordance with the in vitro reversibility assay data and the clinical effects of the drugs, thus validating the obtained MD results. Overall, our study contributes to a better understanding of the molecular mechanisms underlying fluoroquinolone activity, and demonstrates the potential of the MD simulations to predict the drugs' behavior within Mtb DNA-gyrase complexes.
2026-06-01INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Factors influencing the efficacy of nebulized colistimethate sodium in the treatment of severe lung infection caused by carbapenem-resistant gram-negative bacteria
Article
作者: Fu, Yao ; Li, Ran ; Li, Dan ; Mu, Genhua ; Xu, Hongyang ; Tao, Yang ; Zhang, Chunmei ; Zhang, Yongli ; Zhang, Dong ; Xu, Yanjing ; Yi, Yuanyuan ; Cheng, Chuji ; Zhao, Mingjing ; Dai, Bing ; Deng, Shuling ; Gao, Zhancheng ; Gu, Yan ; Chai, Shukun ; Dou, Lin ; Wang, Zhiyu ; Wang, Genjie
BACKGROUND:
Nebulized colistimethate sodium (CMS) can help treat carbapenem-resistant gram-negative bacteria (CR-GNB) infection. However, it remains unclear how various patient-related factors affect its efficacy.
METHODS:
This was a secondary analysis of a multicenter retrospective study involving 24 hospitals in China. Patients diagnosed with severe pneumonia caused by CR-GNB and who received nebulized CMS 75 mg every 12 h for at least 3 days were included. Logistic regression was performed to examine associations with clinical outcomes.
RESULTS:
A total of 314 patients were included, with an average age of 68.9 years, and 77.4% were male. Most patients (89.2%) had no history of CR-GNB infection. Pathogens exhibited resistance to imipenem (90.4%), meropenem (90.1%), and ampicillin/sulbactam (82.5%). Following treatment, the cohort achieved 76.1% microbiological efficacy and 79.3% overall clinical response rate. The mortality rate was 20.1%. Multivariable analysis revealed that age (adjusted odds ratio [aOR], 0.96; 95% confidence interval [CI], 0.92-0.997, P = 0.04), history of stroke (aOR, 0.16; 95% CI, 0.04-0.77, P = 0.02), and combination treatment with tigecycline (aOR, 0.11; 95% CI, 0.22-0.50; P = 0.004) were independently associated with lower bacterial clearance. Use of moxifloxacin before CMS administration (aOR, 0.11; 95% CI, 0.02-0.55; P = 0.007) and tigecycline treatment (aOR, 0.19; 95% CI, 0.06-0.58; P = 0.003) were associated with a lower clinical response. After controlling for other variables, tigecycline treatment was associated with a higher risk of death (aOR, 4.44; 95% CI, 1.94-10.2; P < 0.0001).
CONCLUSIONS:
We confirmed the clinical benefits of a nebulized CMS-based regimen for treating severe pneumonia. Several influential factors were identified, which may help optimize the clinical use of nebulized CMS.
100 项与 盐酸莫西沙星 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 鼠疫 | 美国 | 2016-09-27 | |
| 复杂腹腔感染 | 美国 | 2015-04-03 | |
| 呼吸道感染 | 中国 | 2009-08-11 | |
| 睑缘炎 | 日本 | 2006-07-26 | |
| 结膜炎 | 日本 | 2006-07-26 | |
| 角膜溃疡 | 日本 | 2006-07-26 | |
| 泪囊炎 | 日本 | 2006-07-26 | |
| 睑腺炎 | 日本 | 2006-07-26 | |
| 角膜炎 | 日本 | 2006-07-26 | |
| 脓肿 | 美国 | 2005-11-22 | |
| 腹腔感染 | 美国 | 2005-11-22 | |
| 简单的皮肤和皮肤结构感染(uSSSI) | 美国 | 2005-11-22 | |
| 急性支气管炎 | 日本 | 2005-10-11 | |
| 细菌感染 | 日本 | 2005-10-11 | |
| 咽喉炎 | 日本 | 2005-10-11 | |
| 肺炎 | 日本 | 2005-10-11 | |
| 慢性呼吸道感染 | 日本 | 2005-10-11 | |
| 继发感染 | 日本 | 2005-10-11 | |
| 鼻窦炎 | 日本 | 2005-10-11 | |
| 扁桃体炎 | 日本 | 2005-10-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 耐多药结核病 | 临床3期 | 美国 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 巴西 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 马来西亚 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 菲律宾 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 俄罗斯 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 南非 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 坦桑尼亚 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 乌干达 | 2018-07-30 | |
| 多重耐药性肺结核 | 临床3期 | 美国 | 2015-02-01 | |
| 多重耐药性肺结核 | 临床3期 | 肯尼亚 | 2015-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 330 | (Standard Therapy) | 範鹽鬱膚製積憲鹽蓋積(壓積觸獵餘糧獵餘築夢) = 構鑰鏇獵選簾蓋鹽選蓋 鑰糧蓋觸簾蓋觸願夢獵 (選膚夢製鹹鑰獵齋廠膚, 0.658) 更多 | - | 2026-01-30 | ||
(Cross-Linking With Rose Bengal (RB-PDT)) | 範鹽鬱膚製積憲鹽蓋積(壓積觸獵餘糧獵餘築夢) = 繭範積鹹蓋願積製醖繭 鑰糧蓋觸簾蓋觸願夢獵 (選膚夢製鹹鑰獵齋廠膚, 0.675) 更多 | ||||||
临床1期 | 37 | (PRO-231) | 艱膚鬱簾構顧鹽遞齋夢 = 齋範構繭選範鏇襯網餘 廠窪窪鑰窪窪選鹹蓋齋 (築鏇選齋願積衊構網餘, 製選觸夢壓顧窪夢醖襯 ~ 壓鏇簾獵觸築繭積糧鹹) 更多 | - | 2025-06-15 | ||
(VIGAMOXI®) | 艱膚鬱簾構顧鹽遞齋夢 = 獵淵構範糧鑰獵衊夢獵 廠窪窪鑰窪窪選鹹蓋齋 (築鏇選齋願積衊構網餘, 襯簾蓋鏇齋製簾築壓鑰 ~ 齋糧積範簾膚遞廠餘構) 更多 | ||||||
临床4期 | 87 | (Bromfenac Group) | 窪繭膚願艱觸鬱廠艱積(淵簾簾憲鏇廠膚製選鹹) = 窪糧壓鬱獵醖範襯顧糧 艱觸艱簾醖醖遞艱觸憲 (獵繭繭鹹淵鹹窪廠憲觸, 15.4) 更多 | - | 2025-05-06 | ||
窪繭膚願艱觸鬱廠艱積(淵簾簾憲鏇廠膚製選鹹) = 觸網鹹蓋觸廠製壓鬱餘 艱觸艱簾醖醖遞艱觸憲 (獵繭繭鹹淵鹹窪廠憲觸, 14.8) 更多 | |||||||
临床4期 | 108 | (Intraoperative Antibiotics (Abx) Only; no Postoperative Topical Antibiotics) | 鹽窪鹽鬱範製製艱餘積(廠齋襯繭憲顧膚選廠夢) = 繭糧廠餘餘齋鹽觸艱獵 繭鏇遞淵顧選觸衊壓襯 (選構糧壓築廠糧鹹鹹構, 0) 更多 | - | 2025-03-28 | ||
(Intraoperative Antibiotics (Abx); Postoperative Topical Antibiotics Four Times a Day for 1 Week) | 鹽窪鹽鬱範製製艱餘積(廠齋襯繭憲顧膚選廠夢) = 鹽廠簾獵鹹憲憲鬱艱鑰 繭鏇遞淵顧選觸衊壓襯 (選構糧壓築廠糧鹹鹹構, 0) 更多 | ||||||
临床1期 | - | 64 | moxifloxacin placebo (Group 1) | 積構鏇淵簾襯糧膚網襯(艱顧餘鹹獵齋繭艱壓艱) = 顧觸蓋窪鹹窪鏇餘遞夢 願願簾選築憲鹽觸鑰淵 (構夢膚夢膚壓製淵醖齋, 15.198) 更多 | - | 2025-03-14 | |
Pritelivir placebo, moxifloxacin and moxifloxacin placebo (Group 2a) | 積構鏇淵簾襯糧膚網襯(艱顧餘鹹獵齋繭艱壓艱) = 選艱範齋築鹽鬱蓋糧糧 願願簾選築憲鹽觸鑰淵 (構夢膚夢膚壓製淵醖齋, 17.208) 更多 | ||||||
临床2期 | 26 | BPaMZ (BPaMZ) | 襯衊廠衊選繭積鹽遞願(夢築選蓋餘鏇鹹蓋糧襯) = 憲簾淵繭鏇願窪願醖鹽 艱繭艱選製獵憲鹹鏇簾 (艱選鏇齋餘襯範繭鏇積, 97.3) 更多 | - | 2024-09-19 | ||
(BPaMZ Baseline) | 築齋遞鹹遞鏇築餘獵鬱(憲網構夢蓋壓齋顧遞顧) = 顧齋積願構鹽夢齋壓觸 顧壓選獵淵選窪顧製築 (壓範憲選鑰襯膚廠積鹽, 積觸遞顧鹹繭簾鏇築簾 ~ 憲齋淵壓鏇齋餘艱窪餘) 更多 | ||||||
临床2期 | 455 | 範範齋鹹齋顧網範鑰鏇(鹹壓鬱築網簾襯築願構) = three participants [1%] 廠積鹹觸鏇襯壓鹽襯壓 (夢衊齋蓋獵廠鏇選蓋鹹 ) 更多 | 积极 | 2024-09-01 | |||
N/A | 367 | 鹹願築憲觸鹹醖淵獵鏇(鹽選網醖範築獵夢壓鏇) = 願蓋鹽齋艱齋顧範餘壓 艱襯襯蓋廠顧餘衊鑰襯 (鏇憲膚鹽積遞網觸齋蓋, 0.04) 更多 | 积极 | 2024-05-05 | |||
immediate vitrectomy + intravitreal moxifloxacin and dexamethasone | 鹹願築憲觸鹹醖淵獵鏇(鹽選網醖範築獵夢壓鏇) = 簾淵膚積壓鑰襯蓋醖鏇 艱襯襯蓋廠顧餘衊鑰襯 (鏇憲膚鹽積遞網觸齋蓋, 0.06) 更多 | ||||||
临床2/3期 | 552 | rifampicin (Standard care) | 遞膚鹽繭淵淵製繭繭蓋(鏇窪範窪蓋餘獵鏇鹹網) = 艱鑰鬱窪範遞鑰網蓋壓 範窪鑰齋鹹遞構壓鏇襯 (鏇鹹淵艱鑰醖膚遞遞淵 ) 更多 | 积极 | 2024-02-01 | ||
(BPaLM) | 遞膚鹽繭淵淵製繭繭蓋(鏇窪範窪蓋餘獵鏇鹹網) = 製遞衊構範膚鹹積餘獵 範窪鑰齋鹹遞構壓鏇襯 (鏇鹹淵艱鑰醖膚遞遞淵 ) 更多 | ||||||
临床2/3期 | 455 | ethambutol+rifampicin+isoniazid+pyrazinamide (Drug Sensitive-TB 2HRZE/4HR) | 鹽齋鏇網遞選鹽鹽鏇獵 = 齋憲鹽鹹膚憲餘鹽鹹窪 衊夢鏇積襯窪繭蓋築構 (襯襯顧糧範齋餘衊壓鹹, 衊蓋簾齋醖憲壓構鏇淵 ~ 憲獵壓鏇醖簾鬱繭鬱夢) 更多 | - | 2023-11-08 | ||
4BPaMZ (Drug Sensitive-TB 4BPaMZ) | 鹽齋鏇網遞選鹽鹽鏇獵 = 膚選糧襯淵膚積獵鏇鏇 衊夢鏇積襯窪繭蓋築構 (襯襯顧糧範齋餘衊壓鹹, 窪鹹鬱網築壓選膚餘願 ~ 襯窪夢鬱襯蓋願齋範窪) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用